Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis

  • Se Jin Cho (Department of Radiology, Seoul National University Bundang Hospital) ;
  • Ho Sung Kim (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Chong Hyun Suh (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Ji Eun Park (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center)
  • Received : 2019.12.02
  • Accepted : 2020.03.05
  • Published : 2020.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To categorize the radiological patterns of recurrence after bevacizumab treatment and to derive the pooled proportions of patients with recurrent malignant glioma showing the different radiological patterns. Materials and Methods: A systematic literature search in the Ovid-MEDLINE and EMBASE databases was performed to identify studies reporting radiological recurrence patterns in patients with recurrent malignant glioma after bevacizumab treatment failure until April 10, 2019. The pooled proportions according to radiological recurrence patterns (geographically local versus non-local recurrence) and predominant tumor portions (enhancing tumor versus non-enhancing tumor) after bevacizumab treatment were calculated. Subgroup and meta-regression analyses were also performed. Results: The systematic review and meta-analysis included 17 articles. The pooled proportions were 38.3% (95% confidence interval [CI], 30.6-46.1%) for a geographical radiologic pattern of non-local recurrence and 34.2% (95% CI, 27.3-41.5%) for a non-enhancing tumor-predominant recurrence pattern. In the subgroup analysis, the pooled proportion of non-local recurrence in the patients treated with bevacizumab only was slightly higher than that in patients treated with the combination with cytotoxic chemotherapy (34.9% [95% CI, 22.8-49.4%] versus 22.5% [95% CI, 9.5-44.6%]). Conclusion: A substantial proportion of high-grade glioma patients show non-local or non-enhancing radiologic patterns of recurrence after bevacizumab treatment, which may provide insight into surrogate endpoints for treatment failure in clinical trials of recurrent high-grade glioma.

Keywords

References

  1. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740
  2. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745
  3. Levin VA, Mendelssohn ND, Chan J, Stovall MC, Peak SJ, Yee JL, et al. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. J Neurooncol 2015;122:145-150
  4. Kim JH, Jung TY, Hwang EC, Jung SH, Jung S, Kim IY, et al. Disease progression patterns of bevacizumab responders with recurrent malignant gliomas. Oncol Lett 2017;14:3529-3535
  5. Lu KV, Bergers G. Mechanisms of evasive resistance to antiVEGF therapy in glioblastoma. CNS Oncol 2013;2:49-65
  6. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 2013;19:4392-4403
  7. Wang N, Jain RK, Batchelor TT. New directions in antiangiogenic therapy for glioblastoma. Neurotherapeutics 2017;14:321-332
  8. Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. Am J Pathol 2012;181:1126-1141
  9. Kadambi A, Mouta Carreira C, Yun CO, Padera TP, Dolmans DE, Carmeliet P, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res 2001;61:2404-2408
  10. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001;61:7992-7998
  11. Cachia D, Elshafeey NA, Kamiya-Matsuoka C, Hatami M, Alfaro-Munoz KD, Mandel JJ, et al. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. J Neurooncol 2017;135:75-81
  12. Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, et al. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 2014;82:1684-1692
  13. Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 2011;76:432-437
  14. Tuettenberg J, Grobholz R, Seiz M, Brockmann MA, Lohr F, Wenz F, et al. Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol 2009;135:1239-1244
  15. Bahr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, et al. Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology 2014;83:227-234
  16. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009;91:329-336
  17. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-1206
  18. Barajas RF Jr, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM, et al. The development of reduced diffusion following bevacizumab therapy identifies regions of recurrent disease in patients with high-grade glioma. Acad Radiol 2016;23:1073-1082
  19. Bloch O, Safaee M, Sun MZ, Butowski NA, McDermott MW, Berger MS, et al. Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg 2013;115:1795-1801
  20. Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011;101:319-323
  21. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012;118:1302-1312
  22. Gallego Perez-Larraya J, Lahutte M, Petrirena G, ReyesBotero G, Gonzalez-Aguilar A, Houillier C, et al. Response assessment in recurrent glioblastoma treated with irinotecanbevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 2012;14:667-673
  23. Kim BS, Kim SK, Choi SH, Lee SH, Seol HJ, Nam DH, et al. Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. J Neurooncol 2015;124:101-110
  24. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009;110:173-180
  25. Niyazi M, Jansen NL, Rottler M, Ganswindt U, Belka C. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiat Oncol 2014;9:299
  26. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-787
  27. Schaub C, Greschus S, Seifert M, Waha A, Blasius E, Rasch K, et al. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Oncology 2013;85:191-195
  28. Thomas A, Rosenblum M, Karimi S, DeAngelis LM, Omuro A, Kaley TJ. Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. CNS Oncol 2018;7:7-13
  29. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-W94
  30. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013;66:408-414
  31. Kim KW, Lee J, Choi SH, Huh J, Park SH. Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-Part I. General guidance and tips. Korean J Radiol 2015;16:1175-1187
  32. Lee J, Kim KW, Choi SH, Huh J, Park SH. Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-Part II. Statistical methods of meta-analysis. Korean J Radiol 2015;16:1188-1196
  33. Suh CH, Park SH. Successful publication of systematic review and meta-analysis of studies evaluating diagnostic test accuracy. Korean J Radiol 2016;17:5-6
  34. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
  35. Artzi M, Bokstein F, Blumenthal DT, Aizenstein O, Liberman G, Corn BW, et al. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study. Eur J Radiol 2014;83:1250-1256
  36. Bahrami N, Piccioni D, Karunamuni R, Chang YH, White N, Delfanti R, et al. Edge contrast of the FLAIR hyperintense region predicts survival in patients with high-grade gliomas following treatment with bevacizumab. AJNR Am J Neuroradiol 2018;39:1017-1024
  37. Burger MC, Breuer S, Cieplik HC, Harter PN, Franz K, Bahr O, et al. Bevacizumab for patients with recurrent multifocal glioblastomas. Int J Mol Sci 2017;18. pii: E2469
  38. Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, et al. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. Neuro Oncol 2018;20:557-566
  39. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258-1260
  40. Salloum R, DeWire M, Lane A, Goldman S, Hummel T, Chow L, et al. Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with bevacizumab-based therapy at diagnosis. J Neurooncol 2015;121:591-598
  41. Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, et al. Tumor growth patterns of MGMT-nonmethylated glioblastoma in the randomized GLARIUS trial. J Cancer Res Clin Oncol 2018;144:1581-1589
  42. Shapiro LQ, Beal K, Goenka A, Karimi S, Iwamoto FM, Yamada Y, et al. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys 2013;85:636-642
  43. Toh CH, Liau CT, Wei KC, Castillo M. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab. J Neurooncol 2019;142:149-159
  44. Wick A, Dorner N, Schafer N, Hofer S, Heiland S, Schemmer D, et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 2011;69:586-592
  45. Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, et al. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 2016;18:1434-1441
  46. Yang D. Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria. Neurooncol Pract 2016;3:59-67
  47. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013;31:2205-2218
  48. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014;26:605-622
  49. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012;72:402-407
  50. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233-242
  51. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:143-151